Kisspeptin‑10
10-amino-acid C-terminal kisspeptin fragment – hypothalamic GPR54 → GnRH pulse → LH/FSH. Highest-upstream HPG axis restart agent. Imperial College London Phase I-II ongoing in 2020s; research-emerging.
WHAT IS KISSPEPTIN-10?
Detailed overview
Kisspeptin-10 is the 10-amino-acid C-terminal bioactive fragment of the kisspeptin family (KISS1 gene-product) that binds to the hypothalamic GPR54 (also known as KISS1R) receptor, triggering a GnRH-pulse pattern on arcuate-nucleus GnRH neurons – thereby triggering pituitary LH/FSH release, which activates Leydig cell testosterone production. **Kisspeptin-10 is the highest upstream axis-restart agent in the AAS-PCT arsenal**: the classical PCT tools (Nolvadex, Clomid SERMs) work on pituitary ER blockade (1-level downstream), HCG directly stimulates the testicular Leydig cell LHCGR receptor (3-level downstream), BUT Kisspeptin-10 restarts the hypothalamic GnRH-pulsatility pattern – which is the foundation of the entire physiological functioning of the HPG axis. Jayasena 2017 (PMID 27959703) Phase I-II trial documented that significant LH/FSH spikes + Total Test elevation are achievable 1-2 hours after SC injection. Imperial College London (Waljit Dhillo lab) is currently conducting ongoing Phase II trials in hypogonadism + IVF-fertility indications. **Research-emerging** state: NO approved commercial pharmaceutical exists (Adlumiz pipeline emerging 2025+); UGL peptide-CDMO sourcing is the standard. Practical problem: pulsatile-dosing is impractical in a self-administration context (90-min cycles, pump-protocol required), bolus-dose has limited efficacy.
Mechanism
Hypothalamic GPR54 (KISS1R) agonist → GnRH-pulse → LH/FSH → testicular Test
Dosing
50-200 mcg SC every 90 min (pulse-pump) or 1-2 mg SC bolus daily (community protocol, limited efficacy)
Half-life
~28 minutes (very short – pulsatility pattern is essential)
Onset
LH/FSH spike 1-2 hours after SC
Legal status
NO FDA/EMA pharmaceutical approval; Imperial College London Phase II ongoing 2026, WADA S2 Peptide Hormones banned
Data console
Lab data
Safety
Side effects, stop signs, contraindications
Side effects · 7
- Transient LH/FSH and testosterone surge: rapid hormonal swings that may cause headache, mood lability and short-term libido changes, as documented in clinical trials.
- Receptor desensitization with continuous, non-pulsatile dosing: chronic steady GPR54/GnRH stimulation can paradoxically downregulate the axis and cause LH suppression (the known mechanism of GnRH-agonist therapy).
- Injection-site reactions: subcutaneous administration can cause redness, pain, itching or swelling at the site; this accumulates with frequent daily/hourly dosing.
- Sterility and infection risk: self-handling of research-grade lyophilized peptide (reconstitution, frequent SC injection) can cause skin and soft-tissue infection with non-sterile technique.
- Secondary estradiol rise: peripheral aromatization of the induced testosterone can raise E2, potentially causing water retention or tenderness, of similar magnitude to the HCG axis.
- Fertility/reproductive neuroendocrine effects: kisspeptin strongly drives the reproductive axis, so uncontrolled dosing can disrupt natural cyclicity and spermatogenesis; long-term human safety data are limited.
- Peptide quality risk: UGL sources without HPLC/mass-spec certification may contain degraded or pseudo-peptide, leading to ineffectiveness or unpredictable reactions.
Contraindications · 7
- Pregnancy and breastfeeding, plus pregnant-partner contact risk: kisspeptin is central to reproductive neuroendocrine regulation; avoid due to theoretical fetal HPG-axis effects.
- Hormone-sensitive (androgen- or estrogen-dependent) cancer, e.g. prostate or breast cancer: the induced LH/FSH and testosterone rise can worsen the disease.
- Concurrent GnRH-agonist therapy (Lupron, Zoladex) or other GnRH-pathway agents (gonadorelin): not recommended due to overlapping mechanism and theoretical receptor interaction.
- Structural hypothalamic-pituitary damage or pituitary insufficiency: a peptide acting at the top of the axis cannot substitute downstream replacement where the pituitary response is absent.
- Known hypersensitivity to kisspeptin or formulation excipients (e.g. bacteriostatic water, benzyl alcohol).
- Competitive athletes: prohibited both in- and out-of-competition under WADA S2 Peptide Hormones.
- Untrained self-administering user: the pulsatile pump protocol and sterile reconstitution/injection technique require specialized knowledge; contraindicated without it.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Age-dependent changes in the reproductive axis responsiveness to kisspeptin-10 administration in healthy men.
Ullah H, Nabi G, Zubair H, Shahab M
Changes in the Responsiveness of the Hypothalamic-Pituitary-Gonadal Axis to Kisspeptin-10 Administration during Pubertal Transition in Boys.
Nabi G, Ullah H, Khan S, Wahab F, Duan P, Ullah R, Shireen N, Shahab M
Hypothalamic Response to Kisspeptin-54 and Pituitary Response to Gonadotropin-Releasing Hormone Are Preserved in Healthy Older Men.
Abbara A, Narayanaswamy S, Izzi-Engbeaya C, Comninos AN, Clarke SA, Malik Z, Papadopoulou D, Modi M, Faruqi D, Mustafa R, Bassett P, Lavery S, Trew GH, Patel A, Hu M, Bloom SR, Dhillo WS
Telegram
Have a question about Kisspeptin‑10?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.